XNAS · RLAY
+1.70% · +$0.3300 · Vol 2.2M
Market closed · last close 4:00 PM ET · price as of 16:52:49 ET
Relay Therapeutics, Inc. Common Stock

Relay Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$19.70
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

Score not reportedVeridion does not publish a score-history trend for RLAY until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
NO SCORE SNAPSHOT COVERAGE
AI Analysis
Sovereign

Why is RLAY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for RLAY are being assembled.
About Relay Therapeutics, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
192
Country
US

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$19.13
Day high
$20.29
Day low
$18.85
Previous close
$19.37
52W high
$20.75
-5.06% from high
52W low
$3.22
94% of range
Market cap
$4.2B
EPS
$-1.7100
Beta
1.60
Shares out
217.9M
Volume
2.2M
0.52× rel vol
Avg volume
4.1M
VWAP
$19.94
Price history computed in-house
1W
-1.52%
1M
+24.06%
3M
+17.54%
1Y
+462.86%
YTD
+132.86%
SMA 50 $15.76 · above
SMA 200 $10.70 · above
52W position 94%
Veridion warehouse edge

Warehouse intelligence for RLAY.

Veridion Score
Not reported
Six-factor detail requires Sovereign.
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Related public evidence

Continue the RLAY research trail.

Relationship mapTrace receipt-backed holders and filings around RLAY.Congress disclosuresOpen receipt and filing context for RLAY.MethodologyReview score inputs, coverage rules, and limitations.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

Receipt-backed filing rows for RLAY are being assembled from the latest scheduled snapshot.

Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

RLAY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for RLAY in this window.
Lobbying spend

RLAY lobbying filings, year to date.

Registered lobbying filings matched to Relay Therapeutics, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for RLAY in this window.
Latest news · RLAY
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for RLAY.
Options
Sovereign unlock shows live options positioning for RLAY.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.